In late 2022, the American College of Rheumatology (ACR) issued a position statement on biosimilars  in which they emphasized their strong belief that safe and effective treatments should be available to patients at the lowest possible cost. This is an update of previous position statements .
American College of Rheumatology position statement on biosimilars updated
Biosimilars/General | Posted 16/03/2023 0 Post your comment
ACR states that decisions regarding the approval and use of biosimilars should be approved based on sound science and they consider six observations and guiding principles:
1. Due to their size, complexity and heterogeneity, biologicals (and biosimilars) necessitate more scrutiny in their analytical evaluation than that required for small molecule generics.
2. Clinical data are necessary (in addition to adequate pharmacokinetic and pharmacodynamic studies) to ensure the safety and efficacy of biosimilars, and to allow patients and clinicians to be confident in their use. Long-term post-marketing data for each biosimilar is needed to monitor adverse events.
3. Post-marketing surveillance studies are needed in both children and adults. The Best Pharmaceuticals for Children Act (BPCA) should apply to biosimilars.
4. The US Food and Drug Administration (FDA) labels should clearly indicate whether a biosimilar is interchangeable with the reference biological. They should also clearly state all indications for which a biosimilar is approved and specify whether supporting clinical data for the indication are derived from studies of the biosimilar or the reference biological.
5. When starting new biological therapy, clinicians consider a variety of patient-specific factors which include severity of illness, the most appropriate route of administration and mechanism of action. The ACR supports initial biosimilar use if a biosimilar option of the appropriate treatment biological exists for a patient, however, if a biosimilar option is not available any switches should be approved by the patient insurer.
6. In patients on established therapy, decisions on switching to biosimilars should rest with the prescriber and the patient. The ACR opposes insurer-mandated forced switching to biosimilars and in jurisdictions where substitution by someone other than the prescriber is lawful, the prescriber should be notified upon substitution.
Overall, ACR is supportive of the use of biosimilars and the potential this has to make treatment options more affordable to patients. However, they believe that biosimilars must be administered based on the six points and that decisions regarding administration and switching should lie in the hands of the prescriber only.
American Academy of Ophthalmology biosimilars position statement published
How biosimilar competition in Europe is changing
Shared decision-making and the transition to biosimilars
ASCO issues position statement on biosimilars in oncology
LATIN AMERICAN FORUM
View the latest headline article: La adopción exitosa de biosimilares en Europa y EE. UU.
Browse the news in the Latin American Forum!
Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.
Ver el último artículo de cabecera: La adopción exitosa de biosimilares en Europa y EE. UU.
!Explore las noticias en el Foro Latinoamericano!
Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.
1. American College of Rheumatology. Biosimilars Position Statement [homepage on the Internet]. [cited 2023 Mar 16]. Available from: https://www.rheumatology.org/portals/0/files/biosimilars-position-statement.pdf
2. GaBI Online - Generics and Biosimilars Initiative. ACR position statement on biosimilars addresses naming and substitution [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Mar 16]. Available from:
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2023 Pro Pharma Communications International. All Rights Reserved.
Post your comment
High mannose glycans in biosimilars and their pharmacokinetic impact
Biosimilars in Southern European Hospital Markets: barriers and determinants of uptake
New indication for Cosentyx (secukinumab) biological: hidradenitis suppurativa
Advances for STADA-Xbrane’s Ximluci in Europe, the UK and the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
An update on the joint EMA-HMA statement on interchangeability of biosimilar
Biosimilars switching policies for Canada’s Newfoundland and Labrador, and Yukon
Advancing biosimilar drug development with pharmacodynamic biomarkers
Spanish Psoriasis Group update biosimilar position statement
Post your comment